The group's principal activity is to develop and manufacture small bore vascular grafts or synthetic blood vessels. The vascular grafts, made of chronoflex, are used to replace, bypass or provide a new lining or arterial wall for occluded, damaged, dilated or severely diseased arteries. The group also provides routine vascular access for patients undergoing hemodialysis treatments. The group also develops and manufactures polyurethane-based biomaterials for use in acute and chronically implanted devices. On 07-Apr-2003, the group acquired gish biomedical inc.
